Atossa Therapeutics Inc.
ATOS | NASDAQ
$2.31
+$0.06 (+2.67%)
Sep 22, 2026, 1:47 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 17K | 23K | 8K | 23K | 46.6K |
Gross Profit | n/a | -17K | -23K | -8K | -23K | -46.6K |
Operating Income | -37.14M | -27.62M | -31.38M | -27.69M | -20.52M | -14.61M |
Interest Income | 2.38M | 4.05M | 4.34M | 877K | 6K | n/a |
Pretax Income | -34.77M | -25.5M | -30.09M | -26.96M | -20.61M | -17.83M |
Net Income | -34.77M | -25.5M | -30.09M | -26.96M | -20.61M | -17.83M |
Selling & General & Admin | 15.96M | 13.5M | 14.04M | 12.61M | 11.31M | 8M |
Research & Development | 21.19M | 14.12M | 17.33M | 15.08M | 9.21M | 6.61M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 37.14M | 27.62M | 31.38M | 27.69M | 20.52M | 14.61M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 37.14M | 27.62M | 31.38M | 27.69M | 20.52M | 14.61M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 8.61M | 8.39M | 8.41M | 8.44M | 7.8M | 753.9K |
Shares Outstanding (Diluted) | 8.61M | 8.39M | 8.41M | 8.44M | 7.8M | 753.9K |
EPS (Basic) | -4.04 | -3 | -3.60 | -3.15 | -2.70 | -29.55 |
EPS (Diluted) | -4.04 | -3 | -3.60 | -3.15 | -2.70 | -29.55 |
EBITDA | -34.75M | -25.49M | -30.07M | -26.95M | -20.58M | -14.56M |
EBIT | -34.77M | -25.5M | -30.09M | -26.96M | -20.61M | -14.61M |
Depreciation & Amortization | 16K | 17K | 23K | 8K | 23K | 47K |
Add to Watchlist
Select watchlists to add or remove ATOS